Prostate cancer specific internalizing human antibodies
AssigneeThe Regents of the University of California
InventorsBin Liu, James D. Marks
Life of this patent
Estimating the term…
Abstract
This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.
Claims20
An isolated antibody or antigen-binding fragment thereof that specifically binds the antigen bound by the M10A12 single chain human antibody consisting of SEQ ID NO:23, wherein said isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising the 3 complementarity determining regions (CDRs) of the VH region of the amino acid sequence of SEQ ID NO:23 and a light chain variable region (VL) comprising the 3 CDRs of the VL region of the amino acid sequence of SEQ ID NO:23.
A chimeric molecule, said molecule comprising an effector attached to an antibody that specifically binds the antigen bound by the M10A12 single chain human antibody consisting of SEQ ID NO:23, said antibody comprising a VH comprising the 3 CDRs of the VH region of the amino acid sequence of SEQ ID NO:23 and a VL comprising the 3 CDRs of the VL region of the amino acid sequence of SEQ ID NO:
- 23.
Dependencies are inferred from the claim text.